| U.S. Chamber Action |
| Stand Up for Free Enterprise |
|
|
|
|
| Obesity Medicines Change Lives. Bad Policy Could Harm That. |
| GLP-1 medicines are a medical breakthrough. Price controls would be a step backward. |
| |
Anti-obesity medicines are cutting cardiovascular events by 20% and reducing diabetes, heart disease, and early death for the 42% of Americans living with obesity. This is American innovation at its best.
But: Some in Washington are pushing Most-Favored Nation pricing—tying U.S. drug prices to foreign government rates. Doing so would cut R&D spending by 18.5% and slash clinical trials by 75%. Fewer trials mean fewer cures.
Why it matters: University of Chicago research projects that innovative obesity treatments will generate $94.4 trillion in health value over 30 years. This means healthier workers, fewer hospitalizations, and stronger communities.
Bottom line: Affordability matters for families. Market competition, not government price controls, is what keeps America the best place in the world to develop and receive the next generation of treatments. |
|
|
| |
|
|
|
| U.S. Chamber's Global Partnerships and Marketing |
| Leverage the Chamber's Reach for Your Brand |
| What can your brand achieve with the right partner? |
| |
From thought leadership to business development, the U.S. Chamber's Global Partnerships and Marketing team works with companies like yours to build connection and trust with senior leaders and decision-makers through custom content, experiences, and brand integrations.
Work with our team to:
- Connect with influential decision makers nationwide—from Fortune 500 leaders to small business owners
- Reach the right audience with targeted placements that land with relevance and context
- Drive measurable impact through campaigns designed to achieve engagement and outcomes
All powered by the Chamber’s brand, expertise, and platforms. |
|
|
| |
|
|
|
| Lawsuit Investors Lose in North Carolina |
| When outside investors bankroll lawsuits for profit, families foot the bill. |
North Carolina became the first state to ban third party litigation funding (TPLF)—where outside investors bankroll lawsuits in exchange for a cut of the payout.
Why it matters: Litigation costs American families $4,200 a year. This means higher insurance premiums, medical bills, and grocery receipts. TPLF lets outside investors prolong cases and steer outcomes toward funders' returns rather than plaintiffs' relief.
What we’re saying: "For too long, these outside groups have walked away with massive profits while families and local businesses paid the price." — Stephen Waguespack, President, U.S. Chamber Institute for Legal Reform
Big picture: North Carolina joins a growing national movement. Eighteen states have now passed TPLF reform. Six did in 2025. Four more have in 2026. At the federal level, Congress is weighing both disclosure mandates and a ban on foreign litigation funding. |
|
|
| |
|
|
|
| FOLLOW US ON SOCIAL MEDIA |
|
|
|
|
|
Privacy Policy | Terms and Conditions | Unsubscribe
This e-mail was sent to jcat@stuartmartinchamber.org and contains information directly related to your subscription profile.
This email was sent by: U.S. Chamber of Commerce
1615 H Street, NW
WASHINGTON, DC, 20062, US |
|
|
|
|
|
|
